Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

European countries differ in terms of the impact of clinical issues and additional clinical aspects on the reimbursement policy for ODs. Reimbursement decisions were affected by OD-specific legislation, policies, and EMA authorization status. HTA dossiers and procedures significantly influenced reimbursement decisions, although some ODs were reimbursed regardless of the positive or negative recommendations. ATC codes were significantly correlated with reimbursement status and positive recommendation.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2024-11-19
DOI
https://doi.org/10.3389/fphar.2024.1498386
Citations
5
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
5.65

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

Gisbert Selke, Tanja Mueller, S Jakubowski, Rafał Nowak et al.
5 citations
Frontiers in Pharmacology
Pharmaceutical Economics and Policy
5.65
article

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

Gisbert Selke, Tanja Mueller, S Jakubowski, Rafał Nowak, Outi Salminen, Przemysław Holko, Salvatore Crisafulli, Marc Dooms, Eleanor Grieve, M. Warmuth, Einar Magnússon, Imma Danés, Paweł Kawalec, Lucas Cortial, C. Georgi, Fons Strijbosch
article en
5 citations

Abstract

European countries differ in terms of the impact of clinical issues and additional clinical aspects on the reimbursement policy for ODs. Reimbursement decisions were affected by OD-specific legislation, policies, and EMA authorization status. HTA dossiers and procedures significantly influenced reimbursement decisions, although some ODs were reimbursed regardless of the positive or negative recommendations. ATC codes were significantly correlated with reimbursement status and positive recommendation.

Frontiers in PharmacologyVol. 15
University of Verona (IT), Jagiellonian University (PL), University of Piraeus (GR), University of Strathclyde (GB), Aix-Marseille Université (FR), Administration of Occupational Safety and Health (IS), Vall d'Hebron Hospital Universitari (ES), Health Strat (Kenya) (KE), Institut de Neurosciences de la Timone (FR), Wissenschaftliches Institut der AOK (DE), Ministry of Social Affairs and Health (FI), University of Glasgow (GB)
Uniwersytet Jagielloński Collegium Medicum
Openalex Percentile: Top 4%
Pharmaceutical Economics and Policy
5.65
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.